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Abstract:   
Our present work focuses on the set of genes, which are involved in primary brain tumors – the glioma pathway. These gliomas are mostly malignant 
(cancerous) in nature and are difficult to be cured and that’s why they attract the attention of all the workers. To understand the relative functionality of 
these genes, we analyzed the expression pattern of all genes, using gene expression data, at genomic level, and then to check their universality in all other 
cancers, we compared their expression levels and patterns in all other types of cancers by using gene expression graphs, and observed their expression 
levels in all these cancers, whether they are over or under expressed. We found that every gene has its own unique expression pattern and level and on that 
basis it can be classified. We also found that oncogenes and tumor suppressor genes that were involved in the glioma pathway were showing similar 
expression patterns in other cancers too but their expression level is low.  
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Background:   
Gliomas are among the most aggressive malignant tumors and the most 
refractory to therapy, in part due to the propensity for malignant cells to 
disseminate diffusely through out the brain. Glioma is a type of cancer that 
starts in brain and spine. It arises from glial cells. The most common site of 
gliomas is brain [1].Various workers have used the microarray technology 
to analyze the differential expression of the genes involved in the various 
cancers and related pathways, especially in the case of human [2] Gene 
expression profiling is proven useful in sub-classification and outcome 
prognostication for human glial brain tumors. The analysis of 
biosignificance of the 100s and 1000s of alteration in gene expression 
found in genomic profiling remains a major challenge. Moreover, it is 
increasingly evident that genes do not act as an individual unit, but 
collaboration in overlapping network, the deregulation which is a hallmark 
of cancer [3]. 
 
Over the last few years, the routine use of microarrays has made possible 
the creation of large datasets of molecular information characterizing 
complex biological systems. A single sample for microarray contains 
measurements for around 10,000 genes and hence the amount of data in 
each microarray is too overwhelming for manual analysis [4]. The true 
power of microarray analysis does not come from the analysis of single 
experiment but rather from the analysis of many hybridization to identify 
common pattern of gene expression and hence based on the available 
understanding of the cellular processes, the genes that are contained in a 
particular pathway or that responds to a common environmental challenge 
should be co-regulated and consequently should show similar patterns of 
expression [5]. 
 
Modern experimental techniques such as microarray analysis of gene 
expression, are improving our understanding of both the classification and 
biological basis of complex diseases. While there has been an explosion in 
the volume of raw data available for analysis, there is a widening gap 
between statistically compelling results and their biological interpretation. 
Research oftentimes becomes bogged down in an analytical maze of 
spreadsheets and arbitrary statistical significance thresholds. Tools are 
needed that can efficiently summarize huge amounts of information within 
a biological context. Novel combination of microarray clustering features 
supports such a comprehensive analysis. Combining flexibility, speed, and 
visualization of both statistical and annotative information into a single 
package, hierarchical clustering and k-means clustering fulfills a crucial 
role in comprehensive microarray analysis [6].  
 
The biological interpretation of gene expression microarray results is a 
daunting challenge. For complex diseases such as cancer, wherein the body 
of published research is extensive, the incorporation of expert knowledge 
provides a useful analytical framework. However, unexpected differences 
in survival time of various tumors have generated attempts to search for 
more precise parameters [6]. It has been clear that tumor behavior depends 
mostly on gene expression alterations of various genes at genomic level 
[7], thus the  knowledge of single gene alterations failed to accurately 
define pattern and survival time of various malignant tumors; however, the 
gene expression profiling, based on microarray technology has raised 
hopes  [8]. Our main objective is to perform a comparative analysis of 
expression pattern of various genes involved in the glioma pathway of 
Homo sapiens to understand their relative functionality in this pathway and 
also in various other cancers. Such analysis could be used in regulation of 
the disease by altering the expression pattern of responsible genes. This 
would further provide guidance for drug target. 
 
Methodology: 
We first of all retrieved the genes that are involved in pathway of glioma in 
Homo sapiens from the KEGG database and found that 65 genes are 
involved in the glioma pathway [9]. For the analysis of gene expression 
profile of these all genes we downloaded the microarray data from SMD 
database related to glioma and for their comparative expression analysis 
we also downloaded the data for other cancers i.e. breast, lung, Prostate, 
Liver, Pancreas, and Miscellaneous (various Acute Myeloid Leukemia, 
Cell line cancers, Ovarian Cancers and Skin Cancers) [10]. Before the 
analysis, we processed the whole data by taking gene expression ratio (log2 
values) from the downloaded files. Then the data was normalized for 
missing values, by following the neutral method, which was proposed by 
Alizadeh et al. (2000) for the analysis of diffused large B-cell lymphoma 
[11] and for that we replaced the missing (empty) values with zero. After 
preparation of the working data, we carried the whole analysis in two 
different parts. For comparative analysis of various cancer patterns along 
with the glioma with reference to the known glioma suppressor gene i.e. 
PTEN, p53 and Rb1 and oncogenes i.e. EGFR, MDM2, PDGF family, Bioinformation  Volume 5 
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PDGFR family and CDK4 and analyzed their relative role in all the 
cancers and for that we created gene and sample expression profile and 
converted them in tabular form where each column represents a single 
gene and each row represents a single cancer type (Table 1 in 
supplementary material). Further, for the analysis of comparative 
expression of glioma genes within glioma, we analyzed their gene 
expression profile using all available data for glioma, and then for the 
analysis of comparative expression of these genes in other cancer, we 
analyzed the expression profile of these all genes using the data of all 
cancers except glioma and clumped them. For better and simplified 
understanding, we converted overall expression level (over/under/mix) in 
percentage (Figure 1a and 1b).   
 
 
Figure 1: (A) Gene expression level of all 65 glioma genes in glioma tumors; (B) gene expression level of all 65 glioma genes in overall cancers 
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Discussion: 
In this study we concentrated on the differentially expressed genes that are 
involved in the pathway of glioma and might be involved in the other 
cancers. From the results of this study, expression of glioma pathway 
genes is characterized as given in Table 1 (see supplementary material). 
It depicts that the genes CDKN2A, PTEN, RB1 and TP53 are expressing at 
a lower level than the normal and are also an important cause in causing 
the cancers. This means that these genes are functioning as the tumor 
suppressor genes and whenever they are present in the tissues that we have 
taken into consideration; they are likely to cause the cancer. In contrast, the 
genes CDK4, EGFR, MDM2, PDGFA, PDGFB, PDGFRA and PDGFRB 
are showing an enhanced expression in the cancers and hence show that 
the genes are functioning as the oncogenes in the various types of cancers. 
It means, whenever these genes are over expressing in the tissues type we 
studied, they are expected to cause the cancer in these tissues. Even these 
features were compared in the various other cancers whose data has been 
downloaded from SMD itself [10]. The percentage expression of the 
oncogenes and tumor suppressor genes is almost same in the other cancers 
also, like breast cancer, liver cancer, prostate cancer, lung cancer, 
pancreatic cancer and miscellaneous cancers. Miscellaneous cancers 
involve various Acute Myeloid Leukemia, Cell line cancers, Ovarian 
Cancers and Skin Cancers. By the analysis of relative expression patterns 
of the glioma suppressor and oncogenes in all cancers, we observed that 
CDK4, MDM2, EGFR, PDGFA, PDGFB and PDGFRA have almost 
shown a similar pattern and their percentage for over expression was 
observed to be very high and it was found that they  have barely shown 
under expression. Here it was also observed that except the PFGFA for 
which we did not found sufficient data, on an average all these genes 
showed the same expression percentage in all the cancers that they have 
shown in glioma. Genes CDKN2A, PTEN, RB1, and TP53 were found to 
be very close to each other and shared a comparatively very high 
percentage for under expression pattern and very low percentage for over 
expression in glioma and all other cancers. The percentage expression of 
PDGFRB is quite high for over expression in breast and glioma but for 
other cancers (on an average) it has shown the mixed expression. 
These observations are almost similar as observed by wet lab experiments, 
thus they supported the earlier suggested views that their over expression 
made positive effects on various tumors growth [12, 13, 14], in spite of all 
this, intensive research and clinical trials are already going on PDGF 
receptors to test it as the therapeutic targets [12]. Here we suggest that 
CDK4, MDM2, EGFR, PDGFA, PDGFB and PDGFRA genes can be used 
as the marker because they are robust and can be predicted by any method 
(computational and wet lab). 
 
Detection of comparative expression level of all 65 genes involved in 
glioma pathway (Figure 1a and 1b) suggests that, in glioma cancer most 
of these genes show mixed type of expression levels. Some of them show 
100% over expression and some shows 100% under expression. 
Expression level of mTOR, CALML6 and PDGFA was not mentioned in 
the figure because of the non availability of the sufficient amount of the 
data. It has been shown that to maintain a particular process or biological 
pathway it is essential that genes which are related to that process remains 
active, suppression of such genes results in lost of such activity. On the 
basis of this concept, essential genes can be used as the target to control 
pathway. AKT1, CAMK2B and NRAS genes shows 100% over expression 
in all tumors, it suggests that these three genes work as essential genes and 
might be playing some important role to maintain the glioma pathway. 
Here, essentiality of all these three genes suggests that they could act as 
very good drug targets [15]. Further analysis suggests that ARAF, CCND1, 
CDK4, CDKN1A, MDM2, PIK3CD and SHC1 genes show more than 
60% over expression and rest of the time a mixed expression , thus they 
also can be checked for being probable drug targets. The expression levels 
of these 65 genes were also observed in different cancers (Breast, Lung, 
Prostate, Liver and Pancreas) (Figure 1b) and suggests that, the genes of 
glioma pathway are also active in most of the cancers but their expression 
levels remain very low, thus their contributions in these all cancers seems 
little but positive. 
 
Conclusion: 
Analysis of comparative expression patterns of the genes of glioma 
pathway suggests that the genes CDKN2A, PETN, RB1 and TP53 are 
acting as the tumor suppressor genes, the under expression of which are a 
cause of cancer that we have analyzed and the genes CDK4, PDGFA and 
PDGFB, PDGFRA and PDGFRB, MDM2 and EGFR are over expressing 
at a rate higher than the normal and are acting as oncogenes in these 
cancers. The analyses of gene expression further provide us with the 
knowledge of oncogenes and tumor suppressor genes that can be further 
used in disease profiling. It suggests that the use of gene expression data 
can improve the functional gene annotation of the genes that were 
previously unknown. Further the detailed knowledge of oncogenes and 
tumor suppressor genes can be extended to get some potential drug targets 
against which drugs can be designed.  
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Supplementary materials: 
 
Table 1: Percentage expression of glioma genes in various cancers 
Expression (%) 
 CDK4  CDKN2A  EGFR  MDM2  PDGFA PDGFB PDGFRA PDGFRB PTEN  RB1  TP53 
Glioma  68,0,32 0,65,35  68,32,0  68,0,32  0,0,0  100,0,0 68,32,0 68,32,0  0,50,50  0,100,0  0,68,32 
Breast  75,10,15 25,15,60 78,14,8  60,10,30  68,32,00  90,10,0 50,25,25  90,0,10  20,50,30 0,70,30 0,55,45 
Lung  50,25,25 25,50,25 75,25,0 75,0,25 68,0,32 75,20,5  100,0,0  50,50,0 0,75,25 0,100,0 0,75,25 
Prostate  60,0,32  0,68,32 68,0,32 100,0,0 50,0,50 50,0,50 35,25,40  50,0,50 0,50,50 0,100,0 0,35,65 
Liver  60,20,20 20,40,40 80,0,20 80,0,20 100,0,0 100,0,0  0,25,75 40,20,40 0,100,0 0,75,25 0,40,60 
Pancreas  0,0,100  0,100,0 100,0,0 0,0,100 100,0,0 100,0,0  100,0,0  0,0,100 0,50,50 0,100,0 0,50,50 
Miscellaneous  35,20,45 8,22,70  60,8,32  35,35,30  0,0,100  62,8,32 50,0,50  48,22,30  15,40,45  20,50,30  25,50,25 
C
a
n
c
e
r
 
Overall  %  51,11,38 12,49,39  75,11,14 59,7,34 64,6,30 82,6,12 57,16,27 51,17,32 6,58,36 4,83,13 4,53,43 
(Note: % expression = Over, Under, Mixed expression, respectively) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 